$KPTI

What to make of Karyopharm & selinexor going into BOSTON full dataset as late breaker oral at #ASCO2020 ?

Let’s start w/ the abstract—

PFS
ORR
Lower Peripheral Neuropathy
(Numerically fewer deaths..)

$KPTI

First as to selinexor safety (lower PN) and convenience—

Both advantages flow from fact that SVd is once-weekly, meaning less frequent monitoring visits & less Velcade-related tox (namely, PN):

$KPTI

Now, here’s where it gets really interesting—

PFS & ORR stat sig advantage we know...

But, what about more— what about median Overall Survival?

Let’s start w/ the abstract again:

mOS not reached on SVd vs 25 mo on Vd:

$KPTI

But, it gets more interesting from there... Let’s follow mgmt’s lead:

Numerically smaller number of deaths on SVd is “extremely important” & “somewhat unexpected” given earlier line of Tx where avg time on therapy is much longer:

$KPTI

We know that control arm (Vd) mOS was 25 months — not unexpected, velcade is a known quantity...

What is Unexpected & Important, then?

must be selinexor.

Numerically fewer deaths; mOS not reached; why?

Not just topline ORR, but the quality— “deep responses”:

$KPTI

Oh, and COVID kicker...